Corbett Keeling is pleased to announce that the management team of Speciality European Pharma Limited (“SEP” or “the Company”), has acquired the Company from its venture capital shareholders, with the backing of Juno Pharmaceuticals Inc. (“Juno”), an international speciality pharmaceutical company and leading life science investor.
The team at Corbett Keeling, led by Jim Keeling and Harry Knight, advised the management team on the buy-out, which completed in May 2016.
Commenting on Corbett Keeling, Patrick Banks, Chief Executive Officer of SEP, said: “Corbett Keeling created a way forward, where others could not, at a critical moment for the management team. Their access to the appropriate funders in the UK and overseas, and their ability to move quickly, were both crucial to making this transaction possible.”
Commenting on the Management Buy-Out, Jim Keeling, Chairman of Corbett Keeling, said: “Following the buy-out of SEP, the management team is extremely well placed to grow the business and realise the potential of its product portfolio. Together with backers, Juno, we wish them a successful future partnership.”